Epidemiología y caracterización general de los tumores cerebrales primarios en el adulto
##plugins.themes.bootstrap3.article.details##
Los tumores primarios del sistema nervioso representaron aproximadamente el 1,4 % de los nuevos diagnósticos de cáncer en 2015 y causan el 2,6 % de las muertes por cáncer. Estos tienen una mayor implicación clínica en la población infantil y en adultos jóvenes; y su incidencia disminuye con la edad. Los tumores más frecuentes en los adultos incluyen meningiomas, gliomas y tumores pituitarios. En este artículo se hace una revisión actualizada sobre la epidemiología de los tumores primarios del sistema nervioso, así como las principales características y actualizaciones en el manejo de los tumores más prevalentes en la población adulta.
brain; central nervous system; epidemiology; neoplasiascerebro; epidemiología; neoplasias; sistema nervioso central
2. McNeill KA. Epidemiology of brain tumors. Neurol Clin. 2016;34(4):981-98.
3. Coebergh JW, Van Den Hurk C, Louwman M, Comber H, Rosso S, Zanetti R, et al. EUROCOURSE recipe for cancer surveillance by visible population-based cancer RegisTrees® in Europe: From roots to fruits. Eur J Cancer. 2015;51(9):1050-63.
4. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86.
5. Bray F, Piñeros M. Cancer patterns, trends and projections in Latin America and the Caribbean: A global context. Salud Publica Mex. 2016;58(2):104-17.
6. Rapalino O, Batchelor T, González RG. Intra-axial brain tumors. Handb Clin Neurol. 2016;135:253-74.
7. Pardo, C. Cendales R. Incidencia, mortalidad y prevalencia de cáncer en Colombia 2007-2011. Vol. 1. Bogotá: Instituto Nacional de Cancerologia; 2015.
8. Suárez A, Castellanos M, Simbaqueba A, Gamboa Ó. Aspectos clínicos y demora para el diagnóstico en niños con tumores del sistema nervioso central en el Instituto Nacional de Cancerología de Colombia. Rev Colomb Cancerol. 2011 Jan;15(3):127-34.
9. Baldi I, Engelhardt J, Bonnet C, Bauchet L, Berteaud E, Grüber A, Loiseau H. Epidemiology of meningiomas. Neurochirurgie. 2014;Epub:pii: S0028-3770(14)00112-X.
10. Fathi A-R, Roelcke U. Meningioma. Curr Neurol Neurosci Rep. 2013 Apr;13(4):337.
11. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803-20.
12. Evans DGR. Neurofibromatosis type 2. Handb Clin Neurol. 2015;132:87-96.
13. Anderson JL, Gutmann DH. Neurofibromatosis type 1. Handb Clin Neurol. 2015;132:75-86.
14. Igaz P. MEN1 clinical background. Adv Exp Med Biol. 2009;668:1-15.
15. Alegre M, Puig L, de Moragas JM. The Gorlin syndrome. A review of 11 cases. Rev Clin Esp. 1995 Oct;195(10):684-7.
16. Watkins D, Rouleau GA. Genetics, prognosis and therapy of central nervous system tumors. Cancer Detect Prev. 1994;18(2):139-44.
17. Essig M, Anzalone N, Combs SE, Dörfler A, Lee SK, Picozzi P, et al. MR imaging of neoplastic central nervous system lesions: Review and recommendations for current practice. Am J Neuroradiol. 2012;33(5):803-17.
18. Bellail AC, Olson JJ, Hao C. Current Brain Tumor Imaging. 2014;81(3):397-415.
19. Neglia JP, Robison LL, Stovall M, Liu Y, Packer RJ, Hammond S, et al. New primary neoplasms of the central nervous system in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2006 Nov;98(21):1528-37.
20. Rapalino O, Smirniotopoulos JG. Extra-axial brain tumors. Handb Clin Neurol. 2016;135:275-91. doi: https://doi.org/10.1016/B978-0-444-53485-9.00015-5.
21. Hortobágyi T, Bencze J, Varkoly G, Kouhsari MC, Klekner Á. Meningioma recurrence. Open Med. 2016 Jan;11(1):168-73. doi: https://doi.org/10.1515/med-2016-0032.
22. Pinzi V, Biagioli E, Roberto A, Galli F, Rizzi M, Chiappa F, et al. Radiosurgery for intracranial meningiomas: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017 May;113:122-34.
23. Kaul D, Budach V, Wurm R, Gruen A, Graaf L, Habbel P, et al. Linac-based stereotactic radiotherapy and radiosurgery in patients with meningioma. Radiat Oncol. 2014;9(1):78.
24. Norden AD, Drappatz J, Wen PY. Advances in meningioma therapy. Curr Neurol Neurosci Rep. 2009 May;9(3):231-40.
25. Cohen-Inbar O, Lee C, Sheehan JP. The contemporary role of stereotactic radiosurgery in the treatment of meningiomas. Neurosurg Clin N Am. 2016 Apr;27(2):215-28.
26. Buttrick S, Shah AH, Komotar RJ, Ivan ME. Management of atypical and anaplastic meningiomas. Neurosurg Clin N Am. 2016 Apr;27(2):239-47.
27. Spasic M, Pelargos PE, Barnette N, Bhatt NS, Lee SJ, Ung N, et al. Incidental Meningiomas. Neurosurg Clin N Am. 2016 Apr;27(2):229-38.
28. Bi WL, Dunn IF. Current and emerging principles in surgery for meningioma. Chinese Clin Oncol [Internet]. 2017;6(S1):S7. Disponible en: http://cco.amegroups.com/article/view/15463/15715.
29. Gupta S, Bi WL, Dunn IF. Medical management of meningioma in the era of precision medicine. Neurosurg Focus. 2018;44(4):E3. doi: https://doi.org/10.3171/2018.1.FOCUS17754.
30. Robin AM, Lee I, Kalkanis SN. Reoperation for Recurrent Glioblastoma Multiforme. Neurosurg Clin N Am. 2017;28(3):407-28.
31. Diwanji TP, Engelman A, Snider JW, Mohindra P. Epidemiology, diagnosis, and optimal management of glioma in adolescents and young adults. Adolesc Health Med Ther. 2017;8:99-113.
32. Noorani I, Sanai N. Surgical management of incidental gliomas. Neurosurg Clin N Am. 2017;28(3):397-406.
33. Stupp R, Mason W, Bent M van den, Weller M, Fisher B, Taphoorn M, et al. Radiotherapy plus concomitant and adjuvant temozolomide for globlastoma. N Engl J Med. 2005;352:987-96.
34. Sociedad Española de Neurorradiología. Criterios de respuesta de los tumores cerebrales. Soc Española Neurorradiología [Internet]. 2011;1-16. Disponible en: http://www.senr.org/pdf/section_5/Criterios_respuesta_Tumores_Cerebrales.pdf.
35. Morshed RA, Young JS, Hervey-Jumper SL. Sharpening the surgeon's knife: Value of extent of resection for glioma in the molecular age. World Neurosurg. 2018 Jul 5;117:350-2. doi: http://dx.doi.org/10.1016/j.wneu.2018.06.149.
36. Stepp H, Stummer W. 5-ALA in the management of malignant glioma. Lasers Surg Med. 2018;(April). doi: http://doi.wiley.com/10.1002/lsm.22933 %0A.
37. Šteňo A, Jezberová M, Hollý V, Timárová G, Šteňo J. Visualization of lenticulostriate arteries during insular low-grade glioma surgeries by navigated 3D ultrasound power Doppler: technical note. J Neurosurg. 2016;125(4):1016-23. doi: http://thejns.org/doi/10.3171/2015.10.JNS151907.
38. Moiyadi AV, Shetty PM, Mahajan A, Udare A, Sridhar E. Usefulness of three-dimensional navigable intraoperative ultrasound in resection of brain tumors with a special emphasis on malignant gliomas. Acta Neurochir (Wien). 2013;155(12):2217-25.
39. Lopes MBS. The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol. 2017 Oct;134(4):521-35.
40. Greenman Y. Management of endocrine disease: Present and future perspectives for medical therapy of nonfunctioning pituitary adenomas. Eur J Endocrinol. 2017 Sep;177(3):R113-24.
41. Zhang Y, Wang Z, Liu Y, Zong X, Song M, Pei A, et al. Endoscopic transsphenoidal treatment of pituitary adenomas. Neurol Res. 2008;30(6):581-6.
42. Kassam AB, Prevedello DM, Carrau RL, Snyderman CH, Thomas A, Gardner P, et al. Endoscopic endonasal skull base surgery: analysis of complications in the authors’ initial 800 patients. J Neurosurg. 2011;114(6):1544-68.
43. Cavallo LM, Solari D, Tasiou A, Esposito F, De Angelis M, D’Enza AI, et al. Endoscopic endonasal transsphenoidal removal of recurrent and regrowing pituitary adenomas: Experience on a 59-patient series. World Neurosurg. 2013;80(3-4):342-50. doi: https://doi.org/10.1016/j.wneu.2012.10.008
44. Kalinin PL, Kadashev BA, Fomichev D V, Kutin MA, Astaf’eva LI, Sharipov OI, et al. [Surgical treatment for pituitary adenomas]. Zh Vopr Neirokhir Im N N Burdenko. 81(1):95-107.
45. Rogers A, Karavitaki N, Wass JAH. Diagnosis and management of prolactinomas and non-functioning pituitary adenomas. BMJ. 2014 Sep;349:g5390.
46. Molitch ME. Nonfunctioning pituitary tumors. Handb Clin Neurol. 2014;124:167-84. doi: https://doi.org/10.1016/B978-0-444-59602-4.00012-5.
47. Tampourlou M, Ntali G, Ahmed S, Arlt W, Ayuk J, Byrne J V., et al. Outcome of nonfunctioning pituitary adenomas that regrow after primary treatment: A study from two large UK centers. J Clin Endocrinol Metab. 2017 Jun;102(6):1889-97.
48. Greenman Y, Stern N. Optimal management of non-functioning pituitary adenomas. Endocrine. 2015 Sep;50(1):51-5.
49. Langlois F, Mccartney S, Fleseriu M. Recent progress in the medical therapy of pituitary tumors. Endocrinol Metab [Internet]. 2017;32(2):162-70. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503860/pdf/enm-32-162.pdf
50. Cohen-Inbar O. [Radiosurgery for pituitary adenomas]. Harefuah. 2017 Jan;156(1):45-50.
51. Shore RE, Moseson M, Harley N, Pasternack BS. Tumors and other diseases following childhood x-ray treatment for ringworm of the scalp (Tinea capitis). Health Phys. 2003 Oct;85(4):404-8.
52. Taylor AJ, Little MP, Winter DL, Sugden E, Ellison DW, Stiller CA, et al. Population-based risks of CNS tumors in survivors of childhood cancer: the British Childhood Cancer Survivor Study. J Clin Oncol. 2010 Dec;28(36):5287-93.
53. Walter AW, Hancock ML, Pui CH, Hudson MM, Ochs JS, Rivera GK, et al. Secondary brain tumors in children treated for acute lymphoblastic leukemia at St Jude Children’s Research Hospital. J Clin Oncol. 1998 Dec;16(12):3761-7.
54. Braganza MZ, Kitahara CM, Berrington de González A, Inskip PD, Johnson KJ, Rajaraman P. Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review. Neuro Oncol. 2012 Nov;14(11):1316-24.
55. Interphone Study Group. Brain tumour risk in relation to mobile telephone use: results of the Interphone international case-control study. Int J Epidemiol. 2010 Jun;39(3):675-94.
56. Brossier NM, Gutmann DH. Improving outcomes for neurofibromatosis 1-associated brain tumors. Expert Rev Anticancer Ther. 2015 Apr;15(4):415-23.
57. Maldonado ICM, Contreras LL, García AN, Quintana OB, Rodríguez JA. Clasificación morfológica de meningiomas en una casuística del Hospital Universitario Dr. José E González. Patología (Mex). 2011;49(3):188-95.
58. Goldbrunner R, Minniti G, Preusser M, Jenkinson MD, Sallabanda K, Houdart E, et al. EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol. 2016;17(9):e383-91. doi: http://dx.doi.org/10.1016/S1470-2045(16)30321-7.